What testosterone cypionate is, why the exact product and UK prescribing route matter, and what to ask about monitoring or a clinic transfer.
Testosterone cypionate is an injectable form of testosterone used in replacement treatment. If you are considering it in the UK, the important questions are which exact product is proposed, why it suits your clinical needs, how it will be supplied and who will monitor your treatment.
It is one formulation of TRT, rather than a separate diagnosis or a guarantee of better results. This guide explains the prescribing questions to discuss before starting treatment or moving your existing care to another clinic.
Cypionate is an ester of testosterone: a form that allows testosterone to be released gradually from an oily injection. Products can differ in concentration, other ingredients, packaging and approved instructions. The US product information for Hospira testosterone cypionate, for example, specifies intramuscular use. That US label does not establish UK authorisation or the instructions for another product.
“Test C” is a common abbreviation online. For a medical review, use the full name on your prescription and pack, including the manufacturer and concentration, so your clinician knows exactly what you have been taking.
The BSSM's 2023 UK guidance discusses cypionate among unlicensed short-acting testosterone injections. For a product offered today, confirm its current UK status with the prescribing clinician and dispensing pharmacy. A foreign brand name, overseas approval or a clinic's preferred schedule does not establish a UK marketing authorisation.
The distinction matters:
The GMC's prescribing standards say doctors should usually use appropriately licensed medicines. An unlicensed medicine may be appropriate following an individual assessment where there is a medical reason to meet a specific patient need. The prescriber must be satisfied about the evidence or experience supporting it, explain the decision and arrange responsibility for care and follow-up.
The MHRA's supply guidance sets out the lawful route for unlicensed medicines where an available licensed medicine cannot meet the patient's clinical need. Being available from a seller is not the same as being suitable for you.
Before agreeing to treatment, ask your clinical team to explain:
UK-authorised medicines can be identified by their product licence number, such as a PL or PLGB number. The MHRA Products service provides product information and licence-history documents. Your pharmacist can help you check the actual medicine you receive.
A discussion of cypionate does not mean that a particular clinic will prescribe it. Confirm the medicine and care plan proposed for you before agreeing a transfer or treatment change.
Cypionate and enantate, also spelt enanthate, are different testosterone esters. UK testosterone enantate product information has its own administration and monitoring instructions. Sustanon contains a mixture of four esters, while testosterone gel is applied to the skin. These formats have different practical requirements.
Choosing a formulation involves the diagnosis, response, ingredients, treatment routine and monitoring. There is no basis for choosing solely because an online account calls one ester “best”. The BSSM cautions against assuming that long-term evidence for licensed gels or long-acting testosterone undecanoate automatically applies to unlicensed formulations.
Our testosterone gel versus injections guide explains the broader comparison. A clinician should review a change of product or route; a dose or injection schedule from another person's prescription is not a substitute for your own instructions.
TRT assessment starts with symptoms, properly interpreted testosterone tests and investigation of the cause. The Endocrine Society guideline recommends confirming low testosterone with a repeat morning fasting measurement and assessing suitability before treatment. Wanting a particular injection does not establish a need for TRT.
During treatment, reviews look at benefit and adverse effects as well as the blood-test result. Monitoring can include testosterone, haemoglobin and haematocrit, with other checks selected for your circumstances. Your clinical team should tell you when to take a sample in relation to the actual medicine and prescription. Record when your last dose was taken; do not copy sampling instructions for a different formulation.
Fertility plans need discussion before treatment. Testosterone treatment can suppress sperm production, and cypionate should not be assumed to avoid that effect. See our TRT and fertility guide for the questions to raise.
Tell your prescribing team about new symptoms or treatment concerns. The exact product leaflet and your clinician's advice should guide an individual review. Our TRT side-effects guide explains the wider monitoring and safety questions.
There is no single price that describes both a medicine and the care around it. Ask for a clear quote showing the prescribed product, consultations, monitoring and any separate charges. Compare the same components between providers; a vial price and a monthly care plan describe different purchases.
Use the TRT costs guide to compare published monthly care information. Confirm the exact medicine in your individual quote rather than assuming that a plan includes cypionate.
Share your current prescription and medicine details, diagnostic results, recent monitoring and relevant treatment history. Tell the receiving team when your next prescription is due. They need to review whether they can take over care and which treatment they would recommend; a transfer enquiry does not guarantee continuation of the same product, route or dose.
The guide to switching TRT clinics explains the existing Heracles transfer process. You can also arrange a free switch consultation with Heracles to discuss your current care.
If you have not yet been assessed, read how to get TRT in the UK or explore TRT assessment with Heracles.